Intent to Use. Neither Seller nor any of its Affiliates has filed or submitted to the FDA a Notice of Intent to Use the Priority Review Voucher to obtain a Priority Review.
Appears in 3 contracts
Samples: Asset Purchase Agreement (Argenx Se), PRV Transfer Agreement (Gw Pharmaceuticals PLC), PRV Transfer Agreement (Biohaven Pharmaceutical Holding Co Ltd.)
Intent to Use. Neither Seller nor any of its Affiliates has filed or submitted to the FDA FDA, or instructed or permitted any Third Party to file or submit to the FDA, a Notice of Intent to Use the Priority Review Voucher to obtain a Priority Review.
Appears in 2 contracts
Samples: Asset Purchase Agreement (Argenx Se), Asset Purchase Agreement (Bluebird Bio, Inc.)
Intent to Use. Neither Seller nor any of its Affiliates has filed or submitted to notified the FDA a Notice of Intent intent to Use use the Priority Review Voucher to obtain a Priority Review.
Appears in 2 contracts
Samples: Asset Purchase Agreement (Siga Technologies Inc), Asset Purchase Agreement (Spark Therapeutics, Inc.)
Intent to Use. Neither Seller nor None of Seller, BPI or any of its their respective Affiliates has filed or submitted to the FDA a Notice notification of Intent intent to Use use the Priority Review Voucher to obtain a Priority ReviewVoucher.
Appears in 1 contract
Samples: Asset Purchase Agreement (Biomarin Pharmaceutical Inc)
